Sign In
Buy JNJ
$244.88
+3.88 (+1.61%)
At Close: Jun 25, 2026
Why Johnson & Johnson Stock Was Pulling Back Today
12:41pm, Tuesday, 23'rd Jan 2024
Johnson & Johnson edged out estimates and delivered in-line guidance for 2024. Concerns about legal settlements and competition for drug Stelara seemed to weigh on the stock.
J&J's (JNJ) Q4 Earnings Beat, Darzalex, Stelara Drive Sales
12:06pm, Tuesday, 23'rd Jan 2024
J&J (JNJ) beats estimates for fourth-quarter earnings and sales. Sales of several key drugs like Darzalex, Stelara and Tremfya beat estimates.
Mixed Q4 Earnings Report
12:02pm, Tuesday, 23'rd Jan 2024
Pre-market futures are mixed at this hour, coming off two strong trading days as Q4 earnings season begins to hit its stride. The Dow is -0.55% currently, while the S&P 500 and Nasdaq are +0.21% and +
J&J agrees to pay $700M to settle talc probes in 42 states
11:31am, Tuesday, 23'rd Jan 2024
J&J has maintained that its now-discontinued talc products are safe and do not cause cancer. It previously set aside $400 million to resolve state claims.
Q4 Earnings for J&J, Procter, GE & More
11:26am, Tuesday, 23'rd Jan 2024
Pre-market trading fortunes are mixed for this morning's reportees, including JNJ, PG, GE, MMM and DHI.
Johnson & Johnson posts Q4 earnings beat, $21.4B in revenue
11:22am, Tuesday, 23'rd Jan 2024
Pharmaceutical giant Johnson & Johnson (JNJ) topped fourth-quarter earnings estimates, reporting nearly $21.4 billion in quarterly revenue. Yahoo Finance Health Reporter Anjalee Khemlani monitors how
Johnson & Johnson (JNJ) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
11:00am, Tuesday, 23'rd Jan 2024
The headline numbers for Johnson & Johnson (JNJ) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Str
Johnson & Johnson to Pay $700 Million to Settle Baby Powder Probe
10:07am, Tuesday, 23'rd Jan 2024
The agreement in principle addresses an investigation brought by more than 40 states into the marketing of its talcum-based baby powder.
FDA Demands "Boxed Warning" to CAR T-Cell Therapy Labels
09:10am, Tuesday, 23'rd Jan 2024
The FDA directs companies like NVS, BMY, GILD and others to add "boxed warning" to the labels of their CAR T-cell immunotherapies after it identified adverse events.
Johnson & Johnson undershoots full-year earnings guidance
08:16am, Tuesday, 23'rd Jan 2024
New Jersey-based pharmaceutical giant Johnson & Johnson (NYSE:JNJ) hit top-line expectations in today's annual earnings call, but slightly undershot with its adjusted earnings results. The company rep
Johnson & Johnson's stock price is at a critical turning point
08:12am, Tuesday, 23'rd Jan 2024
Johnson & Johnson NYSE: JNJ had a solid quarter in Q4 despite the impacts of the Kenvue spin-off and the deleveraging of COVID-19 sales. However, little has emerged to catalyze the bulls, although amp
J&J CFO Joseph Wolk on Q4 earnings beat: Near- and long-term looks very strong at the company
08:06am, Tuesday, 23'rd Jan 2024
Johnson & Johnson CFO Joseph Wolk joins 'Squawk Box' to discuss the company's quarterly earnings results, which reported fourth-quarter earnings and revenue that narrowly edged out Wall Street's expec
Aureus' Kari Firestone previews earnings season: JNJ, PG, LMT, NFLX
08:03am, Tuesday, 23'rd Jan 2024
Kari Firestone, Aureus Asset Management executive chairman and co-founder, joins 'Squawk Box' to discuss the latest market trends ahead of earnings season.
J&J Q4 earnings narrowly top expectations
07:20am, Tuesday, 23'rd Jan 2024
Johnson & Johnson (NYSE: JNJ) just reported its financial results for the fourth quarter that slightly topped Street estimates. Its shares are roughly flat in premarket on Tuesday.
Johnson & Johnson Q4 earnings beat estimates amid strength in medtech
06:35am, Tuesday, 23'rd Jan 2024
Johnson & Johnson JNJ, +0.49% said Tuesday it had net earnings of $4.132 billion, or $1.70 a share, for the fourth quarter, up from $3.227 billion, or $1.22 a share, in the year-earlier period. Adjust
